Provided by Tiger Trade Technology Pte. Ltd.

Metsera Inc.

70.50
0.0000
Volume:- -
Turnover:- -
Market Cap:7.43B
PE:-11.96
High:70.50
Open:70.50
Low:70.50
Close:70.50
52wk High:83.86
52wk Low:12.30
Shares:105.38M
Float Shares:64.51M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8924
EPS(LYR):-14.4907
ROE:-134.66%
ROA:-38.77%
PB:22.03
PE(LYR):-4.87

Loading ...

Metsera says will accept superior bids until closing, Bloomberg reports

TIPRANKS
·
Nov 06, 2025

Metsera falls after FTC raises filing concerns over Novo bid

TIPRANKS
·
Nov 06, 2025

US Says Structure of Novo Nordisk Transaction May Reduce Metsera's Incentive to Continue Bringing Drugs to Market

THOMSON REUTERS
·
Nov 06, 2025

BRIEF-U.S. Federal Trade Commission Says It Has Concerns About Novo Nordisk Bid For Metsera - FTC Letter To Metsera

Reuters
·
Nov 06, 2025

FTC Says It Has No Position on Whether the Proposed Novo-Metsera Transaction Abides by Antitrust Law

THOMSON REUTERS
·
Nov 06, 2025

FTC Is Concerned About Novo-Metsera Deal Proceeding Without Filing for Hsr Antitrust Clearance

THOMSON REUTERS
·
Nov 06, 2025

Metsera drops 5% to $69.55 after Bloomberg report of FTC filing concerns

TIPRANKS
·
Nov 06, 2025

Metsera Estimates Novo Nordisk's Latest Bid at Between $69.82 and $70.18 per Share - Metsera Letter to Court

THOMSON REUTERS
·
Nov 06, 2025

Pfizer Has Removed Conditions on Sale of Arch Venture Shares and Metsera Public Statements From Its Metsera Bid - Pfizer Letter to Court

THOMSON REUTERS
·
Nov 06, 2025

Metsera Estimates Value of Pfizer's Latest Proposal at Between $63.29 and $63.33 per Share - Metsera Letter to Court

THOMSON REUTERS
·
Nov 06, 2025

Novo Nordisk U.S. Operations Head Moore: Our Market Research Shows That Compounding Continues to Increase in the U.S.

THOMSON REUTERS
·
Nov 05, 2025

Novo Nordisk U.S. Operations Head Moore: Well Above 1 Million People in the U.S. Are NOW Using Compounded Semaglutide

THOMSON REUTERS
·
Nov 05, 2025

Novo Nordisk CEO: the Chinese Market for Obesity Drug Is Not Growing as Much as We Had Anticipated

THOMSON REUTERS
·
Nov 05, 2025

The AI Stocks Selloff Could be a Bust or a Blip. This Will Decide Which. -- Barrons.com

Dow Jones
·
Nov 05, 2025

Novo Nordisk CEO, on the Obesity Drug Market Race: This Is a Marathon, Not a Sprint

THOMSON REUTERS
·
Nov 05, 2025

Novo Nordisk CEO: No Doubt Seeing Competitor Headwinds but This Is at When We at Our Best and Strongest

THOMSON REUTERS
·
Nov 05, 2025

Novo Nordisk CEO: Cannot Say Whether Novo Will Offer a Still Higher Price for Metsera

THOMSON REUTERS
·
Nov 05, 2025

Novo Nordisk CEO: I Am Very Confident in Our Own Pipeline, but No Matter What Pipeline We Have It Will Not Be Good Enough to Meet Market Demand

THOMSON REUTERS
·
Nov 05, 2025

Novo Nordisk CEO: Must Expand Number of Obesity Drug Candidates We Have

THOMSON REUTERS
·
Nov 05, 2025

Novo Nordisk CEO: Cannot Comment on 'Rumors' of Glp-1 Drug Price Cut Deal With White House

THOMSON REUTERS
·
Nov 05, 2025